Summary
Other Scenarios:
- FRX - GSK
- FRX - SNY
- GSK - ACAM
- SNY - ACAM
| Buyer: | Forest Laboratories, Inc. (FRX) | Last Price: | 45.50 | Market Cap.: | 14.83B |
|---|---|---|---|---|---|
| Target: | Acambis plc (ADR) (ACAM) | Last Price: | 7.21 | Market Cap.: | 3.87B |
Lines of Business Summary:
- Forest Laboratories, Inc. (FRX) competes in 1 industry and 29 product/service groups
- Acambis plc (ADR) (ACAM) competes in 1 industry and 6 product/service groups
- A combined entity will have 0% Product/Service Group overlap
- Forest Laboratories, Inc. (FRX) has 3 and Acambis plc (ADR) (ACAM) has 1 customers that derive significant revenue from each. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
*Healthcare |
|
|
860 |
Biopharmaceuticals |
|
|
311 |
|
Medical Devices |
|
246 |
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 28)
|
Target (Total: 9)
|
Buyer
|
Targetn/a |
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 6)
|
Target (Total: 2)
|
Buyer (Total: 4)
|
Target (Total: 1)
|
Key Financial Summary:
| Metric | Buyer | Target |
|---|---|---|
| Number of Employees | 5,136 | 270 |
| Revenue Per Employee | 591,371.2 | 117,943.6 |
| Total Revenue | 757.8 | 8.0 |
| Total Expenses | 510.8 | 26.8 |
Other Revenue
|
14.6 | 0.0 |
|
Cost of Revenue
|
165.9 | 9.4 |
|
SG&A Expense
|
250.7 | 2.4 |
|
Research & Development
|
94.2 | 15.0 |
|
Other Operating Expense
|
0.0 | 0.0 |
|
Operating Income
|
247.0 | -18.8 |
|
Unusual Income
|
0.0 | 0.0 |
|
Gross Margin %
|
78.11 | -17.39 |
| Metric | Buyer | Target |
|---|---|---|
|
Operating Margin %
|
32.6 | -234.78 |
| Total Assets | 3,483.8 | 229.6 |
| Return on Equity % | 25.55 | -49.33 |
|
Cash+ ST Inv. Per Share
|
4.25 | 2.39 |
| Total Debt | 0.0 | 8.7 |
|
Curr Portion of LTD/Cap Lease
|
0.0 | 0.0 |
| Total Debt to Equity | 0 | 5.56 |
|
LT Debt to Capital
|
0 | 5.26 |
|
Fwd P/E
|
20.31 | n/a |
|
Fwd P/Rev
|
4.96 | n/a |
| Book Value | 3,055.0 | 156.6 |
Individual Company Summary
Focused
Buyer
Focused ():
*Healthcare > Biopharmaceuticals > Neurology
Target
Focused ():
*Healthcare > Biopharmaceuticals > Infectious Diseases > Viral > Vaccines
Business Description
Buyer
Forest Laboratories, Inc. and its subsidiaries develop, manufacture and sell ethical drug products, which require a physician's prescription, as well as non-prescription pharmaceutical products sold over the counter (OTC). The Company's products in United States consist of branded ethical drug specialties marketed directly or detailed to physicians by the Company's Forest Pharmaceuticals, Forest Therapeutics, Forest Healthcare, Forest Ethicare and Forest Specialty Sales forces. The Company's products include Lexapro, Celexa, Namenda, Benicar, Campral, Combunox, RGH-188, GRC 3886, Desmoteplase, CCR1 Antagonists, Milnacipran, Tiazac and Lercanidipine.
Target
Acambis plc is a biopharmaceutical company operating in the infectious disease arena, with a focus on developing new vaccines. The Company's revenues are principally derived by sales of ACAM2000, the investigational product in its smallpox vaccine franchise, which is being sold to governments, even while it undergoes clinical testing. In addition, revenues also come from sales in North America of an oral typhoid vaccine, Vivotif by its sales and distribution operation, Berna Products Corporation. The majority of Acambis' operations are in the United States, with research and development in Cambridge, Massachusetts; manufacturing in Canton, Massachusetts; a sales and marketing operation in Miami, Florida, and a lyophilisation and fill and finish facility in Rockville, Maryland that the Company acquired in May 2005. During the year ended December 31, 2004, Acambis' customer, the United States Centres for Disease Control and Prevention, accounted for 84% of its revenues.
Product Summary
| Sector | Buyer | Target |
|---|---|---|
|
*Healthcare |
|
|
Biopharmaceuticals |
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
|
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
|
|
|
|
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
|
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
|
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
|
|
|
|
Medical Devices |
|
|
|
Drug Delivery
The Drug Delivery Subsector includes medical devices that facilitate the delivery of medications through different anatomical entryways, including blood vessels, skin, the mouth, and the lungs. Common devices in this sector include vascular access catheters, needles, implants, and inhalers.
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
*Healthcare |
|
|
|
Biopharmaceuticals |
|
|
Cardiovascular System |
|
|
Heart Disorders |
|
|
|
Angina |
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat chest pains by preventing the entry of calcium into heart muscle cells.
Buyer Products:
|
|
|
|
Heart Failure (HF) |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat the ineffective pumping of the heart by blocking beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Vascular Disorders |
|
|
|
Hypertension |
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor.
Buyer Products:
|
|
|
|
Angiotensin II Receptor Antagonists/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Endocrinology/Metabolism |
|
|
|
Thyroid Gland Disorders |
|
|
|
Hypothyroidism |
|
|
|
Thyroid Hormones
Therapeutics that treat a deficiency in thyroid activity by supplementing thyroid hormones.
Buyer Products:
|
|
|
|
Immunology |
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Infectious Diseases |
|
|
|
Bacterial |
|
|
|
Antibacterial Agents |
|
|
|
Broad Spectrum |
|
|
|
Antibiotics |
|
|
|
Carbapenems
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Vaccines |
|
|
|
Bacterial |
|
|
|
Single Target |
|
|
|
Typhoid Fever
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause typhoid fever.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.
Target Products:
|
|
|
|
Viral |
|
|
|
RNA Viruses |
|
|
|
Orthomyxovirus |
|
|
|
Influenza A |
|
|
|
Viral Uncoating Inhibitors
Therapeutics that treat viral infections of the respiratory tract caused by Influenza A virus by preventing the removal of the protective shield around the viral genome, thus preventing the release of viral DNA into the host.
Buyer Products:
|
|
|
|
Vaccines |
|
|
|
Viral |
|
|
|
Single Target |
|
|
|
Japanese Encephalitis
Therapeutics that prevent or treat viral infections characterized by inflammation of the brain by producing or artificially increasing immunity to the Japanese B Encephalitis virus.
Target Products:
|
|
|
|
Variola (Smallpox)
Therapeutics that prevent or treat viral infections that cause a diffuse and extensive distribution of lesions by producing or artificially increasing immunity to the Variola virus.
Target Products:
|
|
|
|
Yellow Fever
Therapeutics that prevent or treat viral infections characterized by fever and hemorrhage by producing or artificially increasing immunity to the yellow fever virus.
Target Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Skeletal Disorders |
|
|
|
Joint Disorders |
|
|
|
Fibromyalgia Syndrome (FMS) |
|
|
|
Serotonin/Norepinephrine Reuptake Inhibitors
Therapeutics that treat Fibromyalgia Syndrome by preventing reuptake of serotonin and norepinephrine.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Neurological Disorders |
|
|
|
Alzheimer`s Disease |
|
|
|
N-Methyl-D-Aspartate (NMDA) Receptor Antagonists
Therapeutics that treat the disorders involving the progressive degeneration and death of brain cells by preventing the actions of an amino acid neurotransmitter, N-Methyl-D-Aspartate.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Psychiatric Disorders |
|
|
|
Anxiety |
|
|
|
Generalized Anxiety Disorder (GAD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat anxiety by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Panic Disorder |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat panic disorder by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Social Anxiety Disorder (SAD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Social Anxiety Disorder by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Mood Disorders |
|
|
|
Depression |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat depression by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Obstetrics/Gynecology |
|
|
|
Child Birth/Pregnancy |
|
|
|
Induction/Cervical Ripening |
|
|
|
Prostaglandins
Therapeutics that induce contractions by acting directly on the myometrium thus stimulating myometrial contractions in the uterus.
Buyer Products:
|
|
|
|
Pain Management |
|
|
|
Narcotics |
|
|
|
Analgesics/Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters the both the perception of pain as well as the emotional response to pain.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of pain in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Lower Respiratory Tract Disorders (Lung Disorders) |
|
|
|
Asthma |
|
|
|
Prophylactic Treatments |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat asthma by reducing inflammation in the lung passages with steroids.
Buyer Products:
|
|
|
|
Respiratory Distress Syndrome (RDS) |
|
|
|
Surfactants
Therapeutics that treat RDS by modifying alveolar surface tension and thereby stabilizing the alveoli.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Upper Respiratory Tract Disorders |
|
|
|
Coughs/Colds |
|
|
|
Antitussives
Therapeutics that relieve or prevent coughs.
Buyer Products:
|
|
|
|
Toxicology |
|
|
|
Substance Abuse |
|
|
|
Withdrawal |
|
|
|
Alcohol |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat alcohol withdrawal by increasing the effect of GABA at the relevant neuroreceptors.
Buyer Products:
|
|
|
|
Medical Devices |
|
|
|
Drug Delivery |
|
|
|
Pulmonary Delivery |
|
|
|
Aerosol Therapy |
|
|
|
Vapor Therapy |
|
|
|
Accessories
Auxiliary medical devices designed to assist in the pulmonary delivery of metered dose of medication
Buyer Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
GlaxoSmithKline plc (ADR)
|
|
n/a | 158,330.716 | 19.29 | 18.56 | 4.17 | 4.17 | 28.38 | |
| Buyer | |||||||||
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 158,330.716 | 19.29 | 18.56 | 4.17 | 4.17 | 28.38 | |
|
Teva Pharmaceutical Industries Ltd (ADR)
|
|
n/a | 24,716.755 | 23.00 | 20.97 | 4.71 | 3.22 | 8.43 | |
|
King Pharmaceuticals
|
|
n/a | 4,342.917 | 37.03 | 12.87 | 2.45 | 2.44 | 4.91 | |
|
Neurocrine Biosciences, Inc.
|
|
n/a | 2,521.999 | n/a | 61.40 | 20.36 | 12.27 | 6.46 | |
|
First Horizon Pharmaceutical Corp.
|
|
n/a | 736.904 | 17.86 | 17.69 | 3.41 | 2.64 | 30.28 | |
|
AVANIR Pharmaceuticals
|
|
n/a | 485.591 | n/a | n/a | 20.28 | n/a | 13.02 | |
|
Pain Therapeutics, Inc.
|
|
n/a | 482.218 | n/a | -187.50 | 94.90 | 13.19 | 7.61 | |
|
Discovery Laboratories
|
|
n/a | 426.443 | n/a | -9.55 | 1,779.22 | 33.95 | 11.40 | |
|
DOV Pharmaceutical, Inc.
|
|
n/a | 403.498 | n/a | -7.41 | 42.62 | 18.15 | -144.47 | |
| Target | |||||||||
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 158,330.716 | 19.29 | 18.56 | 4.17 | 4.17 | 28.38 | |
|
sanofi-aventis (ADR)
|
|
n/a | 117,145.313 | n/a | 11.83 | 4.03 | 3.33 | n/a | |
|
Merck & Co., Inc.
|
|
n/a | 76,007.326 | 16.54 | 14.81 | 3.45 | 3.62 | n/a | |
|
Wyeth
|
|
n/a | 65,725.563 | 17.91 | 16.16 | 3.50 | 3.26 | 8.34 | |
|
Baxter International Inc.
|
|
n/a | 24,830.452 | 25.75 | 18.74 | 2.52 | 2.41 | 11.02 | |
|
Solvay SA (ADR)
|
|
n/a | 9,363.535 | 10.18 | n/a | 0.96 | n/a | 2.62 | |
|
Chiron Corporation
|
|
n/a | 8,548.136 | 45.11 | 24.20 | 4.45 | 3.95 | 2.86 | |
|
Crucell N.V. (ADR)
|
|
n/a | 1,009.493 | n/a | -33.30 | 21.91 | 19.66 | 6.10 | |
|
VaxGen, Inc.
|
|
n/a | 334.554 | n/a | -5.37 | 23.40 | 7.53 | 12.55 | |
|
Oscient Pharmaceuticals Corporation
|
|
n/a | 147.874 | n/a | -2.06 | 8.78 | 3.14 | -1.76 | |
|
AVANT Immunotherapeutics, Inc.
|
|
n/a | 143.873 | n/a | n/a | 29.58 | 14.59 | 7.81 | |
|
Vical Incorporated
|
|
n/a | 140.636 | n/a | -5.52 | 11.72 | 8.54 | 1.75 | |
|
SIGA Technologies, Inc.
|
|
n/a | 25.441 | n/a | -9.50 | 3.59 | 2.81 | 56.28 | |
|
DOR BioPharma, Inc.
|
|
n/a | 21.763 | n/a | n/a | 6.80 | n/a | 14.74 | |
|
Berna Biotech AG
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Biovail Corporation (USA)
|
|
n/a | 3,999.447 | 24.59 | 13.41 | 4.32 | 4.27 | 19.41 | |
|
Mack-Cali Realty Corp.
|
|
n/a | 2,901.511 | 25.22 | 13.45 | 4.51 | 4.49 | n/a | |
|
Dendrite International, Inc.
|
|
n/a | 624.979 | 28.43 | 35.90 | 1.43 | 1.43 | 4.61 | |
|
Phase Forward Incorporated
|
|
n/a | 323.020 | 26.92 | 32.31 | 3.71 | 3.11 | 6.92 | |
|
PHC, Inc.
|
|
n/a | 39.998 | 14.45 | n/a | 1.12 | n/a | 7.86 | |
|
H. Lundbeck A/S
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Target | |||||||||
|
Baxter International Inc.
|
|
n/a | 24,830.452 | 25.75 | 18.74 | 2.52 | 2.41 | 11.02 | |
|
Cangene Corporation
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
McKesson Corporation
|
|
33.00% | 16,494.123 | 20.57 | 22.56 | 0.19 | 0.18 | 4.17 | |
|
AmerisourceBergen Corp.
|
|
28.00% | 9,564.722 | 31.53 | 22.55 | 0.17 | 0.17 | 5.14 | |
|
Cardinal Health, Inc.
|
|
25.00% | 30,604.114 | 26.61 | 23.09 | 0.39 | 0.37 | 8.34 | |
|
Neurobiological Tech.
|
|
n/a | 115.805 | n/a | -7.09 | 21.85 | 20.52 | -32.73 | |
| Target | |||||||||
|
Federal Government Agencies (United States)
|
|
84.00% | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Mylan Laboratories Inc.
|
|
n/a | 4,828.630 | 32.80 | 24.11 | 3.87 | 3.83 | 8.82 | |
|
Biovail Corporation (USA)
|
|
n/a | 3,999.447 | 24.59 | 13.41 | 4.32 | 4.27 | 19.41 | |
|
Cypress Bioscience, Inc.
|
|
n/a | 188.519 | n/a | -18.87 | 18.10 | 18.48 | 2.07 | |
|
Neurobiological Tech.
|
|
n/a | 115.805 | n/a | -7.09 | 21.85 | 20.52 | -32.73 | |
|
Merck KGaA
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Sankyo Co. Ltd.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
H. Lundbeck A/S
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Recordati S.A. Chemical and Pharmaceutical Company
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
ChemoCentryx
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
BTG plc
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Merz + Co.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Rotta Research Laboratorium S.p.A.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
PAION GmbH
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
bioMerieux SA
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Gedeon Richter Limited
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Replidyne, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Target | |||||||||
|
sanofi-aventis (ADR)
|
|
n/a | 117,145.313 | n/a | 11.83 | 4.03 | 3.33 | n/a | |
|
Baxter International Inc.
|
|
n/a | 24,830.452 | 25.75 | 18.74 | 2.52 | 2.41 | 11.02 | |
|
Chiron Corporation
|
|
n/a | 8,548.136 | 45.11 | 24.20 | 4.45 | 3.95 | 2.86 | |
|
Cangene Corporation
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Berna Biotech AG
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 2,808.7 | 69.8 | 2,878.5 |
|
Other Revenue
|
50.6 | 0.0 | 50.6 |
| Total Revenue | 2,859.3 | 69.8 | 2,929.1 |
|
Cost of Revenue
|
625.3 | 43.7 | 669.0 |
|
SG&A Expense
|
1,038.9 | 11.3 | 1,050.2 |
|
Depreciation & Amortization
|
0.0 | 0.0 | 0.0 |
|
Research & Development
|
277.8 | 53.4 | 331.2 |
|
Interest Expense
|
0.0 | 0.0 | 0.0 |
|
Other Operating Expense
|
0.0 | 0.0 | 0.0 |
| Total Expenses | 1,942.1 | 108.4 | 2,050.5 |
|
Operating Income
|
917.2 | -38.6 | 878.6 |
| Non Operating Items | |||
|
Interest Expense (Inc.), Net Non-Oprtng
|
0.0 | 0.9 | 0.9 |
|
Other, Net
|
0.0 | 0.0 | 0.0 |
| Income Before Taxes | 917.2 | -32.4 | 884.9 |
| Income Taxes | 247.9 | -5.6 | 242.3 |
| Income After Taxes | 669.4 | -26.8 | 642.6 |
|
Net Income - Excl. Xord. Items
|
669.4 | -26.8 | 642.6 |
|
Net Income - Incl. Xord. Items
|
669.4 | -26.8 | 642.6 |
|
Income Avail. to Common
|
669.4 | -26.8 | 642.6 |
| Share Items | |||
|
Basic Avg. Shares Outstanding
|
336.9 | 53.6 | 390.5 |
|
Basic EPS - Excl. Xord. Items
|
1.96 | -0.25 | 1.65 |
|
Basic EPS - Incl. Xord. Items
|
1.96 | -0.50 | 1.65 |
| Full Dilution Adjustment | 0.0 | 0.0 | 0.0 |
| Fully Diluted Shares Outstanding | 340.7 | 53.6 | 394.3 |
|
F.D. EPS - Excl. Xord. Items
|
1.94 | -0.52 | 1.63 |
|
F.D. EPS - Incl. Xord. Items
|
1.94 | -0.52 | 1.63 |
| Balance Sheet | |||
| Assets | |||
|
Cash and Equivalents
|
892.5 | 103.6 | 996.1 |
|
ST Investments
|
555.3 | 24.4 | 579.7 |
|
Accounts Receivable
|
332.7 | 24.9 | 357.6 |
|
Inventory
|
655.7 | 6.4 | 662.2 |
|
Other Current Assets
|
196.2 | 0.0 | 196.2 |
|
Current Assets
|
2,632.4 | 159.3 | 2,791.7 |
|
PPE
|
526.4 | 0.0 | 526.4 |
|
Accum D&A
|
-154.8 | 0.0 | -154.8 |
|
PPE, Net
|
371.7 | 36.2 | 407.9 |
| Goodwill & Intangibles | 238.9 | 34.1 | 273.1 |
| Long Term Investments | 230.7 | 0.0 | 230.7 |
| Other Assets | 0.0 | 0.0 | 0.0 |
|
Other LT Assets
|
10.0 | 0.0 | 10.0 |
| Total Assets | 3,483.8 | 229.6 | 3,713.4 |
| Liabilities | |||
| Accounts Payable | 172.1 | 60.0 | 232.1 |
| Payable/Accrued | 0.0 | 0.0 | 0.0 |
| Accrued Expenses | 234.2 | 0.0 | 234.2 |
|
ST Debt
|
0.0 | 0.0 | 0.0 |
| Other (Current) Liabilities | 14.5 | 0.0 | 14.5 |
|
Current Liab.
|
420.9 | 60.0 | 480.9 |
|
LT Debt
|
0.0 | 8.7 | 8.7 |
|
Total LT Debt
|
0.0 | 8.7 | 8.7 |
| Deferred Taxes | 7.9 | 2.8 | 10.7 |
|
Other LT Liab.
|
0.0 | 1.4 | 1.4 |
|
Total Liabilities
|
428.8 | 72.9 | 501.7 |
| Shareholders Equity | |||
| Common Stock | 41.1 | 18.6 | 59.8 |
| Additional Paid in Capital | 1,002.9 | 170.6 | 1,173.5 |
| Retained Earnings | 4,111.4 | -32.5 | 4,078.8 |
| Treasure Stock | -2,102.3 | 0.0 | -2,102.3 |
| Other Equity | 1.9 | 0.0 | 1.9 |
|
Total Equity
|
3,055.0 | 156.6 | 3,211.6 |
|
Total Liab. & Equity
|
3,483.8 | 229.6 | 3,713.4 |
|
Shares Outstanding
|
330.9 | 53.6 | 384.5 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | 669.4 | -32.4 | 637.0 |
| CF Depreciation | 35.0 | 7.5 | 42.5 |
| CF Amortization | 49.5 | 0.0 | 49.5 |
| CF Deferred Taxes | 34.9 | 0.0 | 34.9 |
| Other Non-Cash Items | 18.4 | 1.0 | 19.5 |
| Change in Working Capital | -213.4 | -40.2 | -253.6 |
| Total Cash From Operating Activities | 593.9 | -64.1 | 529.8 |
| Investing Cash Flow | |||
| Capital Expenditures | -72.9 | -7.1 | -80.0 |
| Other Investing Cash Flows | -74.2 | -2.8 | -77.0 |
| Total Cash From Investing Activities | -147.1 | -9.9 | -157.0 |
| Financing Cash Flow | |||
| Dividends Paid | 0.0 | 0.0 | 0.0 |
| Purchase Or Sale of Stock | -1,052.7 | 2.3 | -1,050.4 |
| Purchase and Retirement of Debt | 0.0 | 118.2 | 118.2 |
| Other Financing Cash Flow | 0.0 | -45.1 | -45.1 |
| Total Cash From Financing Activities | -1,052.7 | 69.6 | -983.0 |
| Exchange Rate Effects | -13.8 | 0.0 | -13.8 |
| Net Change in Cash | -619.6 | -4.4 | -623.9 |
| Cash Taxes Paid | 283.6 | 9.9 | 293.5 |
| Cash Interest Paid | 0.0 | 6.8 | 6.8 |